Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

240.43USD
24 Oct 2014
Price Change (% chg)

$3.22 (+1.36%)
Prev Close
$237.21
Open
$236.88
Day's High
$240.42
Day's Low
$236.19
Volume
216,901
Avg. Vol
379,126
52-wk High
$249.73
52-wk Low
$145.00

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.33
Market Cap (Mil.): $63,509.78
Shares Outstanding (Mil.): 264.26
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): 514.93 33.21 34.06
EPS (TTM): 0.47 -- --
ROI: 0.38 18.18 17.45
ROE: 0.94 18.85 18.26
Search Stocks

Actavis, Sanofi among bidders for Omega Pharma: Bloomberg

- Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV [COUCKO.UL], Bloomberg reported, citing people familiar with the matter.

21 Oct 2014

Actavis, Sanofi among bidders for Omega Pharma - Bloomberg

Oct 20 - Generic drugmaker Actavis Plc and France's Sanofi SA are among the suitors for privately held Omega Pharma NV, Bloomberg reported, citing people familiar with the matter.

21 Oct 2014

Exclusive: Top Actavis holder, Fidelity, adds Allergan holdings- sources

NEW YORK/BOSTON - Fidelity Investments, the largest shareholder in Actavis Plc , has increased its holdings in takeover-target Allergan in recent months and would be supportive of a potential merger between the two drugmakers, according to people familiar with the matter.

10 Oct 2014

RPT-Actavis deal for Allergan would be huge bet on branded drugs

Oct 8 - If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings.

09 Oct 2014

Actavis deal for Allergan would be huge bet on branded drugs

Oct 8 - If Actavis Plc proceeds with a purchase of Botox maker Allergan Inc for potentially more than $60 billion, it will represent the biggest bet yet by one of the traditional generic drugmakers on the upside of expanding branded medicine holdings.

09 Oct 2014

DEALTALK-Actavis may reap benefits of Valeant's hard work on Allergan

NEW YORK, Oct 8 - Earlier this week, Canada's Valeant Pharmaceuticals International Inc appeared to have its plan to buy Botox maker Allergan Inc all mapped out.

09 Oct 2014

Exclusive: Actavis plans new merger approach for Allergan - sources

NEW YORK - Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday. | Video

08 Oct 2014

Exclusive - Actavis plans new merger approach for Allergan - sources

NEW YORK - Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

08 Oct 2014

Exclusive: Actavis plans new merger approach for Allergan - sources

NEW YORK - Actavis Plc plans to approach Allergan Inc again about a potential merger, as the Botox maker warms up to the possibility of a sale, people familiar with the matter said on Tuesday.

08 Oct 2014

Deals of the day- Mergers and acquisitions

(Adds Swisscom, Vista Equity Partners, Waterland, Coty, Brookfield Asset Management, Actavis Plc, Bright Food, America Movil, Wilbur Ross)

08 Oct 2014

Earnings vs. Estimates

Search Stocks